LONDON : GlaxoSmithKline (GSK) has agreed to acquire BP Asset IX, Inc., a subsidiary of Boston Pharmaceuticals, in a deal worth up to $2 billion to gain access to efimosfermin, a potential treatment for steatotic liver disease (SLD), the companies announced Wednesday. Under the terms of the agreement, GSK will pay $1.2 billion upfront,…